Search

Displaying results 2651 - 2660 of 4238 in total
  1. Drug

    EPI-589

    go.drugbank.com/drugs/DB16041
    Investigational

    EPI-589 is under investigation in clinical trial NCT02460679 (Safety and Biomarker Study of EPI-589 in Participants With Amyotrophic Lateral Sclerosis (ALS)).

  2. Drug

    AZD-5423

    go.drugbank.com/drugs/DB12280
    Investigational

    AZD5423 has been used in trials studying the basic science and treatment of Asthma, Bioavailability and AUC, and Chronic Obstructive Pulmonary Disease (COPD).

  3. Drug

    ADH-1

    go.drugbank.com/drugs/DB05485
    Investigational

    ADH-1 may have utility in a wide variety of cancers as N-cadherin is overexpressed in a variety of tumors. … Poorly differentiated, highly invasive carcinomas are characterized by over-expression of N-cadherin (as opposed to E-cadherin).

  4. Drug

    Umifenovir

    go.drugbank.com/drugs/DB13609
    Investigational

    [A191475,A191412] This dual activity may also confer additional protection against viral resistance, as the development of resistance to umifenovir does not appear to be significant. … [A191475] Umifenovir is currently being investigated as a potential treatment and prophylactic agent for COVID-19 caused by SARS-CoV2 infections in combination with both currently available and investigational

  5. Drug

    Serplulimab

    go.drugbank.com/drugs/DB17451
    ApprovedInvestigational

    Serplulimab is a humanized monoclonal IgG4 antibody that acts as an immune checkpoint inhibitor by targeting the programmed cell death-1 (PD-1) receptor.

    Synonyms: Immunoglobulin g4 (228-proline), anti-(human programmed cell death protein 1) (human-mus musculus monoclonal hlx10 .gamma.4-chain), disulfide with human-mus musculus monoclonal hlx10 .kappa.
  6. Drug

    Xaliproden

    go.drugbank.com/drugs/DB06393
    Investigational

  7. Drug

    Dimenhydrinate

    go.drugbank.com/drugs/DB00985
    ApprovedInvestigational

    [L32995] Early research into dimenhydrinate focused on its role as an antihistamine for urticaria; the treatment of motion sickness was an accidental discovery. … [A233130] Dimenhydrinate, also known as B-dimethylaminoethyl benzohydrol ether 8-chlorotheophyllinate, is indicated to prevent nausea, vomiting, and dizziness caused by motion sickness.

  8. Drug

    Isavuconazonium

    go.drugbank.com/drugs/DB06636
    ApprovedInvestigational

    Due to low solubility in water of isavuconazole on its own, the isovuconazonium formulation is favorable as it has high solubility in water and allows for intravenous administration. … This formulation also avoids the use of a cyclodextrin vehicle for solubilization required for intravenous administration of other antifungals such as voriconazole and posaconazole, eliminating concerns

  9. Drug

    Isopropamide

    go.drugbank.com/drugs/DB01625
    ApprovedVet approvedWithdrawn

    Isopropamide iodide is a long-acting quaternary anticholinergic drug. It is used in the treatment of peptic ulcer and other gastrointestinal disorders marked by hyperacidity and hypermotility.

  10. Drug

    Cambinol

    go.drugbank.com/drugs/DB15493
    Experimental

    This activity is currently being investigated for its use as a cancer treatment.